Plasma-Derived Medicinal Products: Classification and Pharmacovigilance

Purpose and Scope

Plasma-derived medicinal products are biological medicines whose active substances are obtained from human plasma through industrial collection, pooling, fractionation and purification processes. They include important therapeutic proteins such as human albumin, immunoglobulins and coagulation factors. Their pharmacovigilance requires an understanding of both the pharmacology of the final product and the characteristics of a biological supply chain that begins with human plasma as the starting material.

This relationship distinguishes plasma-derived products from many recombinant biological medicines. The therapeutic protein is not simply manufactured from a defined recombinant expression system; its starting material originates from human donors and may be pooled from large numbers of donations before fractionation. Consequently, product quality, pathogen safety, traceability, manufacturing controls and clinical safety are connected across several stages of the product lifecycle.

The article explains the classification and scientific basis of plasma-derived medicinal products before examining the manufacturing pathway, major product families and safety characteristics. It then connects these characteristics with pharmacovigilance, including adverse-event assessment, product and batch identification, infectious-risk surveillance, signal management, quality interfaces, aggregate evaluation and inspection readiness. Individual products are reserved for later product-specific articles.

The scope is medicinal products containing plasma-derived proteins as active substances. The EMA guideline on plasma-derived medicinal products also addresses certain investigational products, plasma-derived proteins used as excipients and ancillary substances, while explicitly distinguishing medicinal products from blood and blood components as such. [1]

What Is a Plasma-Derived Medicinal Product?

A plasma-derived medicinal product is a medicinal product whose active substance is obtained from human plasma through an industrial manufacturing process. Under Article 1(10) of Directive 2001/83/EC, medicinal products based on blood constituents include, in particular, albumin, coagulation factors and immunoglobulins of human origin. The EMA guideline uses this legislative framework and applies specifically to medicinal products with plasma-derived proteins as active substances. [1,2]

This definition is important because plasma itself is a complex biological starting material rather than a single defined molecular substance. A plasma pool contains many proteins, and the manufacturing process separates fractions and further purifies selected proteins into medicinal substances with defined quality attributes. The final medicinal product therefore reflects both the properties of the intended protein and the controls applied to the source material and manufacturing process.

Plasma-derived medicinal products should also be distinguished from blood or plasma used directly for transfusion. Blood and blood components fall under a separate regulatory framework for collection and quality and safety standards, whereas industrially manufactured medicinal products based on plasma-derived proteins are regulated as medicinal products. The distinction matters for pharmacovigilance because the relevant product identity, manufacturing pathway and regulatory controls differ.

Why Plasma as a Starting Material Matters

The use of human plasma creates a chain of dependencies that extends from donor selection and donation testing to pooling, fractionation, purification, viral safety measures, release testing and clinical administration. Each stage addresses a different source of uncertainty. Donor screening and donation testing reduce the likelihood that infectious agents enter the manufacturing pool; manufacturing processes provide additional removal or inactivation capacity; quality controls confirm that the finished product meets defined specifications.

These controls do not eliminate the need for pharmacovigilance. A medicinal product may be administered to large populations over many years, and some safety questions can only be evaluated through post-authorisation clinical experience. In addition, a potential safety concern may arise from pharmacological effects of the active protein, hypersensitivity or other reactions to administration, product-quality issues, or a suspected transmissible-agent event. Pharmacovigilance must therefore operate alongside, rather than instead of, the quality and pathogen-safety systems.

The scientific logic can be expressed as:

human plasma source → controlled collection and testing → pooling and fractionation → purification and safety controls → finished medicinal product → clinical exposure → pharmacovigilance evidence

The chain is important because information from one stage can become relevant to another. A quality investigation may establish facts that affect safety assessment, while a pharmacovigilance observation may prompt review of product quality or traceability.

Major Product Families

Plasma-derived medicinal products are not a pharmacologically uniform class. Their common feature is the source of the active substance, but their mechanisms, indications and safety profiles depend on the particular protein.

The family classification is therefore a starting point rather than a safety conclusion. Immunoglobulins, albumin and coagulation factors all originate from human plasma but have different pharmacology and clinical use. Later articles can address individual families and products in greater depth without repeating the common plasma-derived manufacturing framework established here.

Plasma Fractionation and Product Identity

Industrial plasma fractionation separates proteins according to their physicochemical properties and then applies purification and formulation steps to obtain individual medicinal substances. Historically, fractionation has enabled several therapeutically important proteins to be recovered from the same starting material. Modern processes use multiple controlled stages and may include dedicated viral inactivation or removal steps.

The final product is consequently defined not only by its active protein but also by its manufacturing process, specifications and formulation. Changes to the process can affect product quality attributes and therefore require appropriate comparability and regulatory assessment. Pharmacovigilance should not assume that a process change creates a safety problem, but it should be capable of evaluating emerging clinical evidence in the context of such changes when a plausible safety question arises.

Product identity is especially important when several presentations, manufacturers, batches or related plasma-derived products are used in the same healthcare environment. The pharmacovigilance system should preserve enough information to distinguish the administered product and, when relevant, the batch or lot. This is essential for reconstructing exposure and for investigating a possible product-specific or quality-related pattern.

The Biological and Regulatory Framework

Plasma-derived medicinal products are subject to the general EU medicinal-product and pharmacovigilance framework together with specific scientific and quality requirements for products derived from human plasma. The EMA's current scientific guideline addresses collection and control of starting material, manufacture, quality control, process validation, virus safety and stability. It also identifies the importance of the plasma master file and related requirements for the source material. [1]

The pharmacovigilance framework is provided by the general GVP system and its product-specific consideration for biological medicinal products. EMA confirms that biological medicinal products have dedicated product- or population-specific GVP considerations alongside the general GVP modules. [3]

The regulatory architecture therefore has several connected layers: legislation establishes binding requirements; scientific and GVP guidance explains how those requirements are applied; quality and manufacturing controls address the characteristics of the product; and pharmacovigilance evaluates safety in actual clinical use. These layers should be distinguished rather than treated as one undifferentiated set of obligations.

Development and Manufacturing Characteristics

The pharmacovigilance profile of a plasma-derived medicinal product begins with the characteristics of its starting material and manufacturing process. Unlike a recombinant protein produced from a defined cell substrate, plasma-derived products depend on a biological raw material obtained from donors and assembled into manufacturing pools. The controls applied to that material are therefore part of the product's safety context.

Plasma collection and control of starting material

Plasma used for medicinal-product manufacture is collected under controlled conditions and subject to requirements governing donor selection, donation testing and management of the starting material. The purpose is not to guarantee that every potential hazard is absent from every donation, but to reduce risk and provide a controlled input to subsequent manufacturing steps.

The manufacturing system adds additional barriers. Plasma pools undergo controlled processing, and the manufacturing process is designed with steps that contribute to the removal or inactivation of relevant infectious agents. The EMA guideline specifically addresses virus safety, process validation and the scientific basis for these controls. [1]

Pooling and fractionation

Pooling is a defining characteristic of many plasma-derived products. Multiple donations can contribute to a manufacturing pool, after which fractionation and purification separate proteins into different product streams. Pooling permits efficient recovery and standardisation of therapeutic proteins but also means that a quality or safety question may concern a manufacturing pool rather than a single donor.

For pharmacovigilance, this distinction affects how evidence is interpreted. A report involving a plasma-derived product does not by itself establish a problem with the source plasma, the manufacturing pool or the finished product. Conversely, a cluster involving a particular batch or manufacturing period may warrant investigation across quality and pharmacovigilance systems. The assessment should follow the evidence rather than assuming the source of the problem in advance.

Viral safety

Viral safety is a major scientific characteristic of plasma-derived medicinal products. The overall strategy combines controls on the starting material with manufacturing measures that can remove or inactivate viruses. The effectiveness of a manufacturing process is assessed using appropriate scientific and regulatory approaches, including validation of relevant steps.

This layered approach is important when interpreting post-authorisation safety information. A suspected infectious event after administration may represent an actual product-related transmission, an infection acquired independently of treatment, a diagnostic finding of uncertain significance or another clinical explanation. Pharmacovigilance assessment therefore requires clinical information, product identification, exposure timing and, when relevant, coordination with quality and microbiological investigations.

Non-viral transmissible agents

The biological origin of plasma also creates considerations beyond conventional viral safety. Regulatory and scientific work has addressed transmissible agents such as variant Creutzfeldt-Jakob disease, with specific controls and scientific assessments developed as knowledge and technology have evolved. Such issues demonstrate why the safety framework for plasma-derived products must remain connected to both manufacturing science and post-authorisation surveillance.

A pharmacovigilance system should not convert every theoretical transmissible-agent hazard into an identified risk. The appropriate classification depends on the available evidence, product-specific assessment and regulatory conclusions. Potential concerns should remain distinguishable from established risks and from background infectious disease occurring independently of treatment.

Pharmacological Safety of Major Plasma-Derived Products

The source of the active substance does not determine the complete clinical safety profile. Each plasma-derived protein produces effects according to its physiological role and the clinical setting in which it is administered.

Human albumin

Albumin is a major plasma protein involved in maintenance of oncotic pressure and transport of endogenous and exogenous substances. Clinical use is highly dependent on the indication and the patient's underlying physiological state. Safety assessment must therefore consider the condition being treated, fluid status, dose and rate of administration rather than attributing every clinical event after albumin administration to the product.

Human immunoglobulins

Human immunoglobulin products contain pooled antibodies and are used in replacement and immunomodulatory settings. Different preparations may have different concentrations, formulations, routes and clinical indications. Infusion-related reactions and hypersensitivity are relevant considerations, while some serious events require assessment in relation to patient risk factors, dose, route, product characteristics and temporal association.

The pooled nature of immunoglobulin products also makes accurate product identification important. Several products may be used within the same healthcare system, and a safety report that identifies only "immunoglobulin" may be insufficient for product-specific assessment when several preparations are available.

Coagulation factors

Plasma-derived coagulation factors replace proteins required for haemostasis. Pharmacovigilance must consider both the intended correction of bleeding and potential complications associated with haemostatic treatment. In some settings, inhibitor development can complicate replacement therapy, while thrombosis may be relevant depending on the factor, indication and clinical circumstances.

The distinction between disease-related events and treatment-related events is particularly important in haemostatic disorders. Bleeding can occur because treatment is inadequate, delayed or interrupted, while thrombotic events can arise from disease, treatment intensity or other risk factors. Product-specific assessment therefore requires treatment history and clinical context rather than relying on event counts alone.

Immunogenicity and Immune-Mediated Reactions

Plasma-derived proteins are human proteins and may differ from recombinant products in their molecular composition and manufacturing history. Immunogenicity remains a product- and patient-dependent consideration, but it should not be assumed that a human-origin protein is incapable of generating clinically relevant immune responses.

The interpretation of immune reactions requires separation of several concepts. An acute infusion reaction, hypersensitivity event, anti-drug antibody finding and clinically meaningful neutralising immune response are not synonymous. Their mechanisms, clinical implications and evidentiary requirements differ.

Pharmacovigilance should therefore preserve the clinical phenotype, timing, previous exposure, product identity and relevant laboratory findings. Where immunological testing is available, results should be interpreted in relation to assay characteristics and clinical consequences rather than treated as self-explanatory evidence of causality.

Product Quality and Pharmacovigilance

Quality information can become important to pharmacovigilance when a safety observation raises a plausible product-quality hypothesis. Examples include an unusual cluster associated with a batch, an unexpected change in the clinical presentation of an adverse reaction, a complaint suggesting a product defect, or an infectious event requiring investigation.

The appropriate response is an integrated assessment rather than automatic attribution. Quality functions may investigate manufacturing records, deviations, analytical results and batch history while pharmacovigilance assesses clinical reports and broader safety evidence. Regulatory functions may need to evaluate whether a variation, notification or other regulatory action is appropriate.

The relationship can be represented as:

clinical observation → product identification → safety assessment → quality investigation where indicated → integrated conclusion → appropriate risk-management or regulatory action

This sequence preserves the distinction between evidence and hypothesis. A batch association may justify investigation without proving a batch defect; similarly, a quality deviation may require evaluation without demonstrating that patients were exposed to additional clinical risk.

Traceability Across the Product Lifecycle

Traceability is particularly important for plasma-derived products because the product has a complex source and manufacturing history. The ability to identify the medicinal product, batch or lot, administration date and relevant treatment setting can determine whether a safety observation can be connected to other reports or to a quality investigation.

Traceability should support both retrospective investigation and prospective surveillance. When a potential product-specific signal emerges, the organisation may need to determine which patients received a particular presentation or batch and whether similar events occurred with other batches or related products. The reliability of this analysis depends on the quality of information captured at the point of prescribing, dispensing and administration.

Traceability does not mean that every safety assessment requires complete reconstruction of the manufacturing history. Information should be proportionate to the question being investigated. The operational objective is to preserve sufficient information to reconstruct clinically and scientifically meaningful exposure when necessary.

Biosimilar and Recombinant Alternatives

Some plasma-derived proteins have recombinant or other non-plasma-derived alternatives. Their coexistence creates an important distinction for pharmacovigilance. Products with the same physiological function are not necessarily the same medicinal product, and evidence concerning one source or manufacturing platform should not automatically be transferred to another.

When patients switch between plasma-derived and recombinant products, the treatment history can become important in evaluating adverse events, loss of efficacy, immunogenicity or other outcomes. Accurate product identification and exposure chronology are therefore prerequisites for meaningful interpretation.

The same principle applies when different plasma-derived products containing related proteins are used. Pharmacovigilance should retain the ability to evaluate evidence at the individual product level while considering broader biological and class-level information when scientifically justified.

Pharmacovigilance Across the Product Lifecycle

The pharmacovigilance system for a plasma-derived medicinal product begins before marketing authorisation and continues as the product is used in increasingly diverse populations. Pre-authorisation evidence establishes the known safety profile, while post-authorisation surveillance tests whether that profile remains appropriate as exposure increases, indications expand and new evidence becomes available.

The principal sources of evidence include individual case safety reports, clinical studies, literature, spontaneous and solicited data where applicable, epidemiological studies, aggregate reports, quality information and regulatory assessments. The relative importance of each source depends on the safety question. A suspected infectious transmission event may require a very different evidence set from a signal involving infusion reactions or a pharmacological adverse effect.

Individual case safety reports

Case reports should preserve the information required to identify the actual plasma-derived product and reconstruct the clinical exposure. Relevant information can include product name, strength or presentation, batch or lot where available, route, dose, administration date, indication, concomitant medicines, previous exposure to related products and the clinical course of the event.

The absence of batch information does not make a case unusable. However, when a product- or batch-specific hypothesis arises, missing traceability information can limit the ability to investigate the signal. The pharmacovigilance process should therefore distinguish between information necessary for initial case processing and information that may become important during later assessment.

Signal detection and evaluation

Signals involving plasma-derived products should be assessed using the same general scientific principles that apply to other medicinal products, while incorporating the characteristics of the plasma-derived manufacturing and clinical context. Disproportional reporting, case-series review, literature evidence, clinical plausibility, temporal relationships, exposure data and quality information may all contribute.

An apparent cluster should not automatically be interpreted as a product defect or infectious transmission. Reporting stimulated by publicity, changes in clinical practice, changes in product availability or increased awareness can affect reporting patterns. Conversely, a weak initial signal may warrant further investigation when the potential severity and biological plausibility are high.

Signal assessment should therefore distinguish three questions:

1. Is there evidence that the observed event occurs after exposure?
2. Is there evidence that the medicinal product contributes to the event?
3. If a product contribution is plausible, is the evidence consistent with a pharmacological effect, an immune reaction, a quality issue, an infectious concern or another mechanism?

This separation helps prevent premature conclusions and guides the selection of appropriate follow-up evidence.

Aggregate Evaluation and Benefit–Risk Assessment

Aggregate evaluation places individual reports in the context of the accumulated safety profile. For plasma-derived products, this may require integration of long-term clinical exposure with information on manufacturing changes, product presentations, different indications and related biological products.

The interpretation of event frequency requires an appropriate denominator whenever possible. A large number of reports may reflect extensive use rather than an unusually high incidence. Conversely, rare but serious events may be clinically important even when the number of reports is small. The appropriate measure depends on the available evidence and the nature of the safety question.

Benefit–risk assessment should also reflect the therapeutic role of the product. Many plasma-derived medicines are used for conditions in which replacement of an essential protein or immune function can provide substantial clinical benefit. A safety concern therefore needs to be evaluated against the benefits of treatment, the availability of alternatives and the characteristics of the affected population.

Infectious Safety and Suspected Transmission Events

Suspected transmission of an infectious agent through a plasma-derived medicinal product requires particularly careful coordination. The clinical event, diagnostic evidence, exposure history and product identity should be assessed together with the relevant quality and manufacturing information.

A suspected transmission event should not be equated automatically with confirmed product transmission. Alternative sources of infection, timing of exposure, incubation period, diagnostic uncertainty and epidemiological context can materially affect causality. Where appropriate, investigation may extend to retained samples, manufacturing records, plasma pools, donor information available within the applicable framework and other technical evidence.

The purpose of pharmacovigilance in such a situation is to establish and communicate the clinical safety evidence while the quality system investigates the product and manufacturing dimensions. These activities are complementary. Neither system should substitute for the other.

Manufacturing Changes and Comparability

Plasma-derived products may undergo manufacturing changes during their lifecycle. Changes can involve source-material controls, fractionation, purification, viral inactivation or removal, formulation, analytical methods, facilities or other process elements. Regulatory assessment determines the evidence required to demonstrate that the product remains appropriately controlled.

A manufacturing change is not itself a pharmacovigilance signal. However, post-authorisation safety data can provide additional evidence about the clinical consequences of a change, particularly when a plausible safety hypothesis emerges. The assessment should compare evidence before and after the change while accounting for exposure, patient populations, reporting behaviour and other contemporaneous changes.

The practical interface is therefore a lifecycle control rather than a one-time exercise. Quality and regulatory functions evaluate the technical and regulatory consequences of the change, while pharmacovigilance evaluates relevant clinical evidence. Where the evidence converges, additional action may be justified; where it does not, the uncertainty should remain explicit.

Special Clinical Situations

Certain clinical circumstances require particular attention because they can complicate attribution of adverse events.

Patients receiving repeated or lifelong therapy

Repeated exposure can generate extensive treatment histories and may change the clinical context over time. The pharmacovigilance record should distinguish current exposure from previous exposure to the same or related products when that information is relevant to the safety question.

Switching between products

Patients may switch between plasma-derived products or between plasma-derived and recombinant alternatives. A safety assessment following a switch should preserve the chronology of each product exposure. Without that chronology, attribution may be unnecessarily imprecise.

Multiple indications

The same plasma-derived protein may be used in different clinical settings. Background disease, concomitant therapy and expected clinical outcomes can therefore vary substantially. Aggregate assessments should avoid treating all exposure as clinically homogeneous when the underlying populations differ.

Paediatric and vulnerable populations

Some plasma-derived medicines are used in children or patients with severe underlying disease. Background event rates, treatment necessity and the feasibility of alternative therapy may differ from the general population. Safety assessment should therefore retain relevant population characteristics rather than relying solely on overall reporting frequencies.

Roles and Interfaces

Effective surveillance requires defined interfaces between pharmacovigilance and other functions.

Responsibilities should be sufficiently clear that a safety question can be escalated promptly without uncertainty about ownership of the relevant evidence. The functions should retain their distinct responsibilities while contributing to a common assessment when the evidence crosses organisational boundaries.

Evidence and Records

The evidence supporting plasma-derived pharmacovigilance should permit reconstruction of both exposure and reasoning. Depending on the question, relevant records may include case reports, product and batch information, administration records, quality investigations, manufacturing-change documentation, signal assessments, literature reviews, epidemiological analyses, aggregate reports and regulatory decisions.

Records should demonstrate what information was available, what uncertainty remained, which alternatives were considered and why a particular conclusion or action was reached. For a suspected product-quality or infectious event, the interface between pharmacovigilance records and quality-investigation records becomes particularly important.

The objective is not to retain every conceivable piece of information in every case. It is to maintain sufficient traceability that an experienced reviewer can reconstruct the safety assessment and determine whether the evidence supports the conclusion.

Common Failure Modes

The following are illustrative process scenarios rather than claims about specific inspection findings.

Loss of product identity

A report records only "immunoglobulin" or "factor concentrate" despite several products being available. Product-specific signal assessment and traceability are consequently weakened.

Failure to capture batch information when relevant

Batch information is treated as unnecessary for all cases, making later investigation of a product-quality or cluster hypothesis difficult.

Treating plasma origin as a mechanism of harm

An adverse event is attributed to the fact that a product is plasma-derived without considering the pharmacology of the active protein or the clinical circumstances.

Treating a suspected infection as confirmed transmission

A temporal association is interpreted as proof of product transmission without adequate diagnostic, epidemiological and product-specific evidence.

Treating a manufacturing change as proof of changed safety

An adverse event occurring after a process change is attributed to the change without accounting for exposure, reporting behaviour, population changes and other evidence.

Ignoring treatment history during switching

The assessment does not reconstruct previous exposure to related products, limiting interpretation of immunogenicity, loss of efficacy or other events.

Overlooking background disease

Events that are expected consequences of the underlying disorder are attributed to treatment without adequate clinical assessment.

These failure modes share a common problem: they break the chain between product identity, exposure, clinical evidence and conclusion. Effective pharmacovigilance preserves that chain while allowing the evidence to remain proportionate to the safety question.

Inspection Perspective

An inspection of pharmacovigilance activities for a plasma-derived medicinal product could examine whether the organisation has translated the product's scientific and manufacturing characteristics into effective surveillance controls. The following are illustrative inspection questions, not claims about prescribed findings.

• Can the organisation identify the exact plasma-derived product involved in a safety report?
• Can relevant batch or lot information be retrieved when a product- or quality-specific hypothesis arises?
• Can treatment history be reconstructed when patients have received multiple related or alternative biological products?
• Are suspected infectious events assessed using appropriate clinical, epidemiological, product and quality evidence?
• Can pharmacovigilance demonstrate appropriate escalation to quality and regulatory functions when a product-quality hypothesis arises?
• Are manufacturing changes evaluated through defined interfaces between quality, regulatory and pharmacovigilance functions?
• Are signal assessments able to distinguish reporting patterns from changes in clinical risk?
• Are aggregate evaluations appropriately contextualised by exposure, indication and background disease?
• Are decisions and uncertainties documented sufficiently to reconstruct the assessment?
• Can the organisation demonstrate that risk-management measures and follow-up activities remain appropriate to the current evidence?

The inspection focus is effectiveness rather than the existence of procedures alone. A written process does not demonstrate control if product identity cannot be established, relevant records cannot be retrieved or cross-functional escalation fails in practice.

Practical Implementation

A proportionate operating model for plasma-derived medicinal products can be organised around seven linked controls.

The controls should be adapted to the product and its clinical use. An immunoglobulin used for repeated infusion may require different operational emphasis from a coagulation factor used in episodic replacement therapy. A product with a specific infectious-safety concern may require stronger interfaces with quality and microbiology. A product used across multiple indications may require more detailed population and exposure stratification.

Actionable Checklist

Before considering pharmacovigilance controls for a plasma-derived medicinal product adequately established, the organisation should be able to demonstrate that:

This checklist is an operational aid. It does not create additional legal requirements beyond those established by applicable legislation and regulatory guidance.

Relationship With the Wider Pharmacovigilance Framework

Plasma-derived medicinal products are managed within the general EU pharmacovigilance system. Individual case management, signal management, aggregate reporting, risk management, safety communication, quality systems and inspection processes remain governed by the applicable general framework. The product-specific layer adds the scientific context needed to apply those processes effectively to medicines derived from human plasma.

This distinction is important. Treating a plasma-derived medicine as an ordinary protein without considering source-material and manufacturing characteristics can obscure important safety questions. Treating plasma-derived pharmacovigilance as an entirely separate system can instead duplicate established processes. The appropriate model is a common pharmacovigilance architecture supported by product-specific controls for traceability, infectious safety, manufacturing interfaces and clinical interpretation.

The relationship can be represented as:

general GVP processes + plasma-derived product knowledge + source and batch traceability + quality interfaces + clinical evidence = effective plasma-derived medicinal-product pharmacovigilance

The preceding biological-product articles provide the general taxonomy and explain why biological characteristics matter to safety surveillance. This article establishes the plasma-derived family framework. Subsequent articles can then examine particular product groups, such as immunoglobulins or plasma-derived coagulation factors, without repeating the entire biological and manufacturing foundation.

Key Takeaways

Plasma-derived medicinal products are biological medicines whose active substances originate from human plasma and are obtained through industrial manufacturing processes. Albumin, immunoglobulins and coagulation factors are important examples, but the family is pharmacologically heterogeneous.

Their pharmacovigilance cannot be separated from the characteristics of the starting material and manufacturing process. Donor controls, plasma pooling, fractionation, purification and viral-safety measures form a sequence of controls that reduce manufacturing and infectious risks. Pharmacovigilance provides the post-authorisation clinical surveillance needed to determine whether the safety profile observed in practice remains consistent with the accumulated evidence.

The source of the active substance does not itself determine causality. An adverse event after a plasma-derived medicine must be assessed in relation to the active protein, indication, dose, route, timing, patient characteristics and alternative explanations. Suspected infectious transmission and suspected product-quality problems require additional coordination with quality and regulatory functions, but suspicion should not be confused with confirmation.

Accurate product identification and traceability are central operational requirements because several related products may be used within the same healthcare environment. Batch information may become particularly important when a cluster or quality hypothesis arises. The ability to reconstruct treatment history is also important when patients switch between plasma-derived and recombinant products or between different plasma-derived products.

Effective surveillance therefore combines the general EU pharmacovigilance framework with scientific understanding of plasma-derived products and their manufacturing context. The objective is a defensible chain from product source and identity through exposure, clinical observation, evidence integration, assessment and appropriate action.

References

1. European Medicines Agency. Guideline on plasma-derived medicinal products. EMA/CHMP/BWP/706271/2010. Current effective version. The guideline addresses collection and control of starting material, manufacture, quality control, process validation, virus safety and stability of plasma-derived medicinal products.
2. Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use, as amended. Relevant provisions concerning medicinal products based on blood constituents and pharmacovigilance.
3. European Medicines Agency. Good pharmacovigilance practices (GVP). Current GVP framework, including product- or population-specific considerations for biological medicinal products.
4. European Medicines Agency. Guideline on the scientific data requirements for a plasma master file (PMF). Applicable EMA scientific guidance concerning the plasma starting material used for plasma-derived medicinal products.
5. European Medicines Agency. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to variant Creutzfeldt-Jakob disease risk. Relevant scientific guidance concerning transmissible-agent risk.
6. European Commission. EudraLex, Volume 4, Good Manufacturing Practice Guidelines, Annex 14: Manufacture of Medicinal Products Derived from Human Blood or Plasma.
7. European Pharmacopoeia. Human plasma for fractionation and applicable monographs for plasma-derived medicinal products. European Directorate for the Quality of Medicines & HealthCare.
8. International Council for Harmonisation. ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. Applicable principles for evaluation of manufacturing changes where relevant.

Regulatory Note

The legal requirements applicable to plasma-derived medicinal products arise from EU pharmaceutical legislation and the applicable implementing framework. EMA scientific guidelines and GVP provide regulatory guidance and recommendations for applying those requirements. Operational controls, checklists and interpretive frameworks in this article are presented as practical approaches and should not be treated as additional legal requirements unless the applicable legislation or guidance expressly establishes them.

The article describes family-level principles. The identified risks, potential risks, missing information, regulatory status and risk-management measures of an individual plasma-derived medicinal product must be established from its current product-specific regulatory documentation, including applicable product information and regulatory assessments. Current legislation and guidance should be verified before product-specific regulatory or operational decisions are made.